COMPOSITION HAVING IMPROVED WATER SOLUBILITY AND BIOAVAILABILITY
Disclosed are: a composition having improved water solubility and bioavailability, containing sorafenib and a polymethacrylate copolymer; and a preparation method therefor.
1 . An oral composition having improved water solubility and bioavailability, comprising sorafenib or a pharmaceutically acceptable salt thereof, and a polymethacrylate copolymer.
2 . The composition according to claim 1 , wherein the polymethacrylate copolymer is a cationic polymer having dimethylaminoethyl methacrylate.
3 . The composition according to claim 2 , wherein the polymethacrylate copolymer is poly (butylmethacrylate-co-(2-dimethylaminoethyl) methacrylate-co-methylmethacrylate).
4 . The composition according to claim 1 , wherein the polymethacrylate copolymer has a weight average molecular weight of 3,000 to 200,000 g/mole.
5 . The composition according to claim 1 , wherein the polymethacrylate copolymer is in a granular or powder state.
6 . The composition according to claim 1 , comprising 0.05 to 5 parts by weight of polymethacrylate copolymer based on 1 part by weight of sorafenib.
7 . The composition according to claim 1 , wherein the pharmaceutically acceptable salt of sorafenib is sorafenib tosylate.
8 . The composition according to claim 1 , which is in the form of a solid oral formulation.
9 . A method for preparing the oral composition having improved water solubility and bioavailability according to claim 1 , comprising:
1) step of mixing sorafenib or a pharmaceutically acceptable salt thereof with a polymethacrylate copolymer; and
2) step of forming an oral formulation with the mixture of step 1).